Greater Boston
Seasoned supply chain leader with 15 years of experience. Expert in global supply planning, launch coordination, and process optimization; proven track record in enhancing forecast accuracy and supply chain resilience. Recognized for leadership potential and adept at cross-functional collaboration and talent development.
• Manage team of planners to ensure uninterrupted supply to patients and drive forecast improvements across the global supply chain • Leading launch planning for a new molecule in US, EU, Japan, and other global markets. Medicine received priority review designation from the FDA and launch planning timeline condensed to 10 months with a supply chain based in China. • Driving more robust S&OP process for oncology portfolio by increasing engagement from commercial teams and supplying sites. Process has resulted in 20% forecast accuracy improvements for key markets and reduced at-risk inventory through increased oversight.
• Lead cross-functional team and coordinate end-to-end supply chain activities for a growing global oral solid dose brand to ensure on-time, in-full supply to patients in more than 40 countries, supporting $800 million in revenue. • Launched a new medicine in Taiwan and Japan in collaboration with another large multinational pharmaceutical company. Coordinated external partners to ensure timely, compliant deliveries. Supported label expansion and provided uninterrupted supply following the resulting demand increase. • Identified and implemented strategies which increased supply chain stability. Improvements include right sizing inventories, activating a second supply source, and building more flexible processes. These changes have strengthened supplier relationships and increased customer satisfaction. • Ensured launch readiness for a new global injectable medicine with breakthrough designation in the US.
• Serve as core team member for a commercial product launch in China. Work directly with global partners to ensure continuity of launch supply and compliant international logistics and importation. • Work with the program team for a late-stage clinical asset to develop robust cost models, ensure commercial manufacturing capacity is available and resilient, and partner with the manufacturing sciences team to drive efficiency across the supply chain. • Manage key commercial product CMO relationships with direct oversight for supply projections, international shipping and logistics, issue resolution, and change management to ensure uninterrupted product supply. Negotiated $2.6MM in product cost avoidance, a 50% reduction. •Lead monthly S&OP process for all commercial programs to ensure stakeholder alignment including: demand review, supply planning, and meeting coordination. Organize cross-functional team to ensure all stakeholders are engaged and have their issues addressed. •Responsible for API and finished good supply continuity. Developed, track, and report key metrics including inventory levels, on-time-in-full performance, and forecast accuracy. Work cross-functionally to drive improvement. •Oversee state distribution licenses to ensure compliance. •Manage the inventory and distribution of the reference standard and control materials programs to ensure proper global lab support across all regions and stakeholders.
•Managed the finished goods inventory to support $2B in revenue across multiple product lines, including two newly launched products, to ensure 100% on time and in full delivery to patients. •Redesigned and implemented a new excess and obsolete inventory tracking process to reduce complexity, improve accuracy and traceability, while cutting preparation time in half. •Provided interim drug product and drug substance planning support including on-going production planning, long term supply strategy, as well as various quality and regulatory initiatives. • Redesigned monthly production hand off process with external manufacturing partners, enhanced forecast adherence tracking, and align the organization on production and release priorities on a weekly basis.
• Analyzed packaging and distribution options for a new orphan drug program to ensure 100% on time and in full delivery to patients around the world. Presented recommendations to management. • Mapped the supply chain for key products and identified opportunities to reduce cycle times and inprocess inventories without impacting customer service levels.
Developed strategies to reduce cost and ensure supply across Hospira’s multinational manufacturing and supply chain network. Key accomplishments: • Youngest employee to be named manager at time of promotion. • Developed a $200MM proposal to upgrade aging equipment, one of the largest capital projects in company history, and successfully championed the project through the management approval process up through the C-suite. • Performed feasibility study including a gap assessment and data collection to lay the foundation for a logistics and distribution plan to supply the full portfolio of products to 6 continents from the existing manufacturing footprint in a cost-competitive manner. Project considered full supply chain implications including manufacturing, primary and secondary packaging, multi mode distribution channels. The initial focus was products sourced from Tamil Nadu, India for use in South America. • Conducted initial assessment of a new cost saving technology and presented recommendations to executive leadership. The recommendation was accepted resulting in a long-term partnership arrangement expected to deliver a 30% annual cost reduction across a 400MM-unit product line. Assessment included a base business benchmarking and valuation across two production sites and 300+ SKUs. • Analyzed the product registration strategy for the world’s largest injectable manufacturing site, located in Andhra Pradesh, India, and identified key cost reductions and adjusted the development schedule to capture savings 3 years ahead of the previous schedule. • Led full analysis of the manufacturing footprint for a $175MM product line, spanning 4 internal manufacturing sites and 15 third party manufacturers. Developed a strategy to reduce product costs and maximizing internal assets while minimizing additional investment. The project is expected to improve the utilization and operational efficiency while ensuring stable supply across the global network.
Support Hospira's global operations and quality strategies by working across functional areas and levels of management to evaluate and financially value business options. Projects focus on the global manufacturing footprint for the company and include decisions around sourcing, bricks and mortar expansion, divestment and acquisition. Key accomplishments: • Worked closely with operations stake holders to develop a network optimization strategy to reduce manufacturing costs across a $1 billion portfolio spanning 4 manufacturing sites; identified 50% cost reductions versus the incumbent strategy. Presented the recommendation to the CEO and CFO, which was endorsed and subsequently approved by the Board of Directors • Coordinated cross-functional efforts of R&D, engineering, and external suppliers, developing robust cost estimates for several pipeline delivery system projects, each utilizing new technology and processes, resulting in strategic partnerships and continued funding for the development programs. • Led make vs. buy analysis for components touching $600MM in end product sales; presented recommendation to operations leadership and provided on-going support to the project manager
Served as primary financial analyst supporting Large Volume Solutions, Nutritional products, and Drug Delivery products lines. Key accomplishments: • Partnered with 3 marketing managers, each managing a different business line, to develop rolling and annual sales and margin forecast covering a total of $500MM in sales (1/8 of the company's total sales). Ensured consistent forecasting for interrelated products and worked cross functionally to resolve inventory and supply discrepancies across the US network. • Analyzed market opportunities including competitive captures, new product launches, and base business sustainability. • Consolidated monthly results and identify key business drivers to present to senior management; reconciled the marketing demand forecast with the operations and supply chain production schedules to quantify risks to and opportunities in the financial plan. • Led the valuation of a book of business generating $100MM sales annually. Partnered with marketing, supply chain, and corporate strategy to understand the full strategic and financial implications of divesting the business. The valuation was presented to the CEO and served as a critical decision factor.